title: Varenicline, smoking cessation, and neuropsychiatric adverse events.
abstract: OBJECTIVE
  In 2009, the U.S. Food and Drug Administration issued a black box warning for varenicline regarding neuropsychiatric events. The authors used data from randomized controlled trials and from a large Department of Defense (DOD) observational study to assess the efficacy and safety of varenicline.
  
  
  METHODS
  The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders. The authors also analyzed a large DOD data set to compare acute (30-day and 60-day) rates of neuropsychiatric adverse events in patients receiving varenicline or nicotine replacement therapy (N=35,800) and to assess reports of anxiety, mood, and psychotic symptoms and disorders, other mental disorders, and suicide attempt.
  
  
  RESULTS
  In the randomized controlled trials, varenicline increased the risk of nausea (odds ratio=3.69, 95% CI=3.03-4.48) but not rates of suicidal events, depression, or aggression/agitation. It significantly increased the abstinence rate, by 124% compared with placebo and 22% compared with bupropion. Having a current or past psychiatric illness increased the risk of neuropsychiatric events equally in treated and placebo patients. In the DOD study, after propensity score matching, the overall rate of neuropsychiatric disorders was significantly lower for varenicline than for nicotine replacement therapy (2.28% compared with 3.16%).
  
  
  CONCLUSIONS
  This analysis revealed no evidence that varenicline is associated with adverse neuropsychiatric events. The evidence supports the superior efficacy of varenicline relative to both placebo and bupropion, indicating considerable benefit without evidence of risk of serious neuropsychiatric adverse events, in individuals with and without a recent history of a psychiatric disorder.
authors.forename: Robert D
authors.initials: RD
authors.lastname: Gibbons
authors.forename: J John
authors.initials: JJ
authors.lastname: Mann
mesh_terms: D000328:Adult; D000374:Aggression / Q000187:drug effects; D017109:Akathisia, Drug-Induced / Q000175:diagnosis; D001552:Benzazepines / Q000009:adverse effects* / Q000627:therapeutic use; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use; D003863:Depression / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000150:complications; D009325:Nausea / Q000139:chemically induced; D064887:Observational Studies as Topic; D011595:Psychomotor Agitation; D011810:Quinoxalines / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016540:Smoking Cessation / Q000523:psychology*; D059020:Suicidal Ideation; D013406:Suicide, Attempted / Q000523:psychology; D061485:Tobacco Use Cessation Devices / Q000009:adverse effects*; D016896:Treatment Outcome; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline
references.citation: BMJ. 2009 Oct 01;339:b3805
references.pmid: 19797344
references.citation: Biol Psychiatry. 2011 Jun 1;69(11):1075-82
references.pmid: 21295286
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006103
references.pmid: 17253581
references.citation: JAMA Psychiatry. 2013 May;70(5):522-33
references.pmid: 23536105
references.citation: Biometrics. 1986 Mar;42(1):121-30
references.pmid: 3719049
references.citation: Drug Saf. 2009;32(2):119-35
references.pmid: 19236119
references.citation: Drug Saf. 2011 May 1;34(5):375-95
references.pmid: 21513361
references.citation: Addiction. 2013 Jan;108(1):203-10
references.pmid: 22812921
references.citation: Drug Saf. 2009;32(6):499-507
references.pmid: 19459717
references.citation: Drug Saf. 2010 Apr 1;33(4):289-301
references.pmid: 20297861
references.citation: PLoS One. 2011;6(11):e27016
references.pmid: 22073240